March 31st 2023
Oncology nurse experts review their experiences with newcomers for the treatment of advanced endometrial cancer and exchange best practices in caring for this population.
Rucaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer
December 30th 2022Maintenance therapy with rucaparib monotherapy improved progression-free survival compared with placebo. However, the treatment also significantly elevated anemia and neutropenia rates in this setting.
Fertility and Other Treatment Considerations for Patients With Advanced Endometrial Cancer
December 7th 2022The panel shares how they determine a treatment regimen for patients with advanced endometrial cancer taking into consideration fertility and family planning, hereditary conditions, and comorbidities.
Zimberelimab Monotherapy Proves Safe, Effective in PD-L1–Positive Cervical Cancer
December 5th 2022Zimberelimab demonstrated encouraging efficacy with a tolerable safety profile in patients with PD-L1–positive recurrent or metastatic cervical cancer who had progressed after first- or subsequent-line, platinum-containing chemotherapy.
Conversations with Patients With Advanced Endometrial Cancer Before and After Diagnosis
November 29th 2022Nurse Practitioners Kathleen Lutz and Kimberly Halla describe the conversations they have with patients with advanced endometrial cancer before and after diagnosis and the common questions they hear.
Initial Consultation of Patients With Advanced Endometrial Cancer
Kimberly Halla, NP, explains the staging of endometrial cancer and the standards for biomarker testing at her institution.
Symptoms and Diagnosis of Endometrial Cancer
Kimberly A. Spickes, CNP, gives an overview of the typical symptoms women with endometrial cancer present with, discusses how these symptoms are similar and different from those seen with other gynecologic malignancies, and reviews risk factors for endometrial cancer.
Mirvetuximab Soravtansine-gynx Gets Go Ahead in Platinum-Resistant Ovarian Cancer
November 15th 2022Mirvetuximab soravtansine-gynx, an antibody drug conjugate, has received accelerated approval for platinum-resistant ovarian cancer. The prescribing label comes with warnings for visual toxicities, pneumonitis, and peripheral neuropathy.
HRD, BRCA Status May Inform PARP Inhibitor Suitability in Advanced Ovarian Cancer
November 12th 2022During the 40th Annual Chemotherapy Foundation Symposium, Eirwen M. Miller, MD, evaluated the safety and efficacy profiles of different PARP inhibitor therapies for patients with advanced ovarian cancer.